MAM
Resultrix appoints Tanmay Mohanty as India COO
MUMBAI: Resultrix – A Performics Company, owned by Publicis Groupe, has appointed Tanmay Mohanty as chief operating officer for its Indian operations.
Mohanty moves in from Interactive Media And Communication Solutions Ltd. where he was COO id8 Labs. He will report to Resultrix Global COO Gulrez Alam.
Founded in 2008, Resultrix was recently acquired by Publicis. The performance-based digital marketing agency, now functions as part of the Performics bouquet.
Alam added, “It‘s great to have Tanmay on board with Resultrix. We are looking at strengthening our leadership team at Resultrix as we continue with our focus on being at the forefront of the ever evolving digital and interactive services industry. Our clients will benefit from Tanmay‘s vast professional expertise spanning across multiple industries. As Resultrix‘s success story continues, Tanmay‘s insights and leadership will give that extra fillip to take it to the next level.”
Mohanty, with an experience of close to 14 years, has handled management portfolios in the past at companies like Jasubhai, Merchant Media, Dalal Street and Urja Communications. He has experience in the fields of marketing, advertising, brand management, direct sales, BTL, strategic account management, business development and administration.
Mohanty said, “Resultrix has an excellent track record as a leading player in the search and interactive services industry. I look forward to working with the talented and dynamic team at Resultrix and being a part of the company‘s future.”
Resultrix provides services like search engine marketing (SEM), search engine optimisation (SEO), web design and development, web analytics, social media marketing and display advertising. Resultrix has offices in India (Mumbai and Delhi), Seattle, Singapore and Dubai.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
